Concordia Shanghai Breaks Ground on Visionary New Rittmann Center
SHANGHAI, June 13, 2025 /CNW/ -- Concordia International School Shanghai is set to break ground on a major redevelopment of the Rittmann Center, expanding the iconic facility into a modern, 13,710-square-meter multi-purpose hub designed to support student excellence in academics, the arts, athletics, and wellness.
Named after former Head of School Dr. David Rittmann, the Rittmann Center was first completed in December 2007, with a purpose to enhance the school's creative arts education.
More than five times the size of the current building, the new Rittmann Center marks one of the largest facility investments in the school's history. Designed to serve students across all divisions, it embodies Concordia's commitment to innovation, sustainability, and holistic education.
The new center will house:
An eight-lane, 25-meter competition pool with spectator seating for 240
A professional-grade theater with seating for over 500—a major upgrade from the current 330
Purpose-built music classrooms for band, choir, and strings
Six dedicated practice rooms, three ensemble rooms, and a 170m² drama studio
Four expansive art studios filled with natural light and designed for creative exploration
Two underground floors and four above ground, maximizing space while maintaining a compact campus footprint
A green roof and infrastructure built to meet LEED II certification standards, continuing the school's focus on sustainability
Architects from Ennead have worked closely with the school to shape a building that's not only functional but inspiring, incorporating advanced acoustic treatments, energy-efficient HVAC systems, and student-centered design principles to support 21st-century learning and performance.
"The Rittmann Center has long been a space where students shine," said Dr. Eric Semler, Head of School. "This new facility will take that to the next level—empowering students to explore their passions, build confidence, and thrive in a community that celebrates their talents."
Construction will begin after the end of the 2024–25 school year and is expected to be completed by July 2027. To minimize disruption to learning, the school has implemented:
Phased construction scheduling tied to school breaks
Sound barriers, vibration dampeners, and dust suppression systems
Dedicated traffic flow systems to avoid student movement areas
"This is more than a building project - it's an investment in our students' future. It's about creating an environment where future generations can learn, perform, and grow," added Dr. Semler.
About Concordia International School Shanghai
Founded in 1998, Concordia International School Shanghai is a co-educational day school that offers a comprehensive American-style education to students from Preschool through High School. Located in Jinqiao, an international community in Shanghai's Pudong New Area, we are dedicated to cultivating the unique gifts of our students in any areas they are passionate about. Our approach focuses on nurturing every student through a journey of personal and academic growth, offering innovative academic programs, enriching extracurricular activities, and instilling strong character and values.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
Lotto Max - A $75 million jackpot and an estimated 12 Maxmillions in the next draw Français
MONTRÉAL, Aug. 16, 2025 /CNW/ - In the next Lotto Max draw, slated for Tuesday, August 19, the prize pool will be $87 million and include a $75 million jackpot and an estimated 12 Maxmillions. Lotto Max continues to churn out winners in Québec Lotto Max players in Québec have won over $4.009 billion since its launch in 2009. In total, there have been 48 jackpot wins in the province, including 3 of $70,000,000—the largest jackpots ever won in Québec—in the February 25 and October 9, 2020, and June 7, 2022, draws. One $65,000,000 jackpot, four $60,000,000 jackpots, five $55,000,000 jackpots, and nine $50,000,000 jackpots have also been won in Quebec. In addition to these jackpot wins, Lotto Max players in Québec have also won a total of 248 Maxmillions prizes, each worth $1 million, and 151 shares of Maxmillions prizes. Draw results are available online at About Loto-Québec Loto-Québec has been delivering entertainment to Quebecers for over 50 years, and its operations benefit Québec as a whole. Last year, the corporation paid out almost $1.8 billion in prizes to winners across Québec. Major prize winners are listed on the Winners page in the Lotteries section of Read their stories. The responsible commercialization of lottery and gaming products is central to Loto-Québec's operations. The corporation has been granted the highest internationally recognized certification in responsible gaming by the World Lottery Association.
Cision Canada
7 hours ago
- Cision Canada
Media advisory - Canada and Sweden advance their collaboration Français
STOCKHOLM, Sweden, Aug. 15, 2025 /CNW/ - The Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, will meet with Ebba Busch, Sweden's Deputy Prime Minister and Minister for Energy, Business and Industry in Stockholm to deepen Canada–Sweden relationship. They will be joined by the Honourable Stephen Fuhr, Secretary of State (Defence Procurement), and Pål Jonson, Sweden's Minister for Defence. Date: Monday, August 18, 2025 Time: 8:30 p.m. (Central European Time) Location: Stockholm, Sweden Note to media: This is a media spray only. Photo and video opportunity will be available at the top of the meeting. Members of the media are asked to contact Isabella Orozco-Madison at [email protected] to receive event location details and confirm their attendance. Stay connected SOURCE Innovation, Science and Economic Development Canada
Cision Canada
7 hours ago
- Cision Canada
ZYUS Life Sciences Announces Closing of Second Tranche of Unit Offering
SASKATOON, SK, Aug. 15, 2025 /CNW/ - ZYUS Life Sciences Corporation (the " Company") (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that, further to its press release dated July 29, 2025, it has closed the second tranche (the " Second Tranche") of its non-brokered private placement (the " Offering") of units of the Company (each a " Unit") for up to CAD $1,000,000. Under the Second Tranche of the Offering, a further 140,845 Units were issued for aggregate gross proceeds of CAD $100,000. The aggregate gross proceeds raised in the Second Tranche and first tranche of the Offering (which closed on July 29, 2025) (the " First Tranche") is approximately $0.42 million. The Company has issued a total of 591,126 Units each priced at $0.71 per Unit in the First Tranche and the Second Tranche. Each Unit consists of one common share of the Company (a " Common Share") and one Common Share purchase warrant (each Common Share purchase warrant, a " Warrant"), whereby each Warrant entitles the holder to acquire one Common Share at a price of $0.95 for a period of twenty-four months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms (the " Acceleration Provision"). In accordance with the Acceleration Provision, if the volume-weighted average trading price of the Common Shares is greater than $3.00 for a period of 5 consecutive trading days on the TSX Venture Exchange (the " TSXV"), the Company will have the right to accelerate the expiry date of the Warrants. Proceeds of the Offering will be used for general corporate and working capital purposes. No finder's fees were paid in connection with the Offering. The Units were offered by way of private placement pursuant to exemptions from prospectus requirements under applicable securities laws. All securities issued under the First Tranche are subject to a hold period expiring November 30, 2025, and all securities issued under the Second Tranche of the Offering are subject to a hold period expiring December 16, 2025, in accordance with applicable securities laws and the policies of the TSXV. The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States or to, or for account or benefit of, U.S. persons except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States. About ZYUS Life Sciences Corporation ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit or follow us on X @ZYUSCorp. Cautionary Note Regarding Forward-Looking Statements This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, receipt of TSXV final acceptance, closing of any additional tranche of the Offering and use of proceeds from the Offering. Any such forward-looking statements may be identified by words such as "expects", "anticipates", "intends", "contemplates", "believes", "projects", "plans", "will" and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, obtain TSXV final acceptance, closing of any additional tranche of the Offering and use of proceeds from the Offering are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
